OBJECTIVES: To determine the potential impact of genetic testing and pharmacogenomics on healthcare delivery and costs. STUDY DESIGN: Literature review. METHODS: We examined 3 examples: (1) BRCA1/2 testing for breast cancer risk, (2) HER2/neu overexpression testing to guide drug treatment in women with breast cancer, and (3) CYP2C9 testing before the use of the anticoagulant warfarin. We discussed each genetic testing example from the perspective of the patient, provider, insurer, industry, government, and society. RESULTS: The expanded use of genetic information offers many potential clinical benefits, but also many economic challenges. One of those challenges will be managing the impact of genetic testing on healthcare delivery and costs. CONCLUSIONS: Systematic, evidence-based technology assessments and economic evaluations will have to be used to guide the incorporation of genomics into clinical practice. More research also will be needed to assess patient preferences and willingness to pay for genomic technologies; how providers can assess and use genomic technologies; and how the industry, insurers, and government can best balance the relevant costs and benefits.
OBJECTIVES: To determine the potential impact of genetic testing and pharmacogenomics on healthcare delivery and costs. STUDY DESIGN: Literature review. METHODS: We examined 3 examples: (1) BRCA1/2 testing for breast cancer risk, (2) HER2/neu overexpression testing to guide drug treatment in women with breast cancer, and (3) CYP2C9 testing before the use of the anticoagulant warfarin. We discussed each genetic testing example from the perspective of the patient, provider, insurer, industry, government, and society. RESULTS: The expanded use of genetic information offers many potential clinical benefits, but also many economic challenges. One of those challenges will be managing the impact of genetic testing on healthcare delivery and costs. CONCLUSIONS: Systematic, evidence-based technology assessments and economic evaluations will have to be used to guide the incorporation of genomics into clinical practice. More research also will be needed to assess patient preferences and willingness to pay for genomic technologies; how providers can assess and use genomic technologies; and how the industry, insurers, and government can best balance the relevant costs and benefits.
Authors: Ann Chen Wu; James P Kiley; Patricia J Noel; Shashi Amur; Esteban G Burchard; John P Clancy; Joshua Galanter; Maki Inada; Tiffanie K Jones; Jonathan A Kropski; James E Loyd; Lawrence M Nogee; Benjamin A Raby; Angela J Rogers; David A Schwartz; Don D Sin; Avrum Spira; Scott T Weiss; Lisa R Young; Blanca E Himes Journal: Am J Respir Crit Care Med Date: 2018-12-15 Impact factor: 21.405
Authors: Ann Chen Wu; Charlene Gay; Melisa D Rett; Natasha Stout; Scott T Weiss; Anne L Fuhlbrigge Journal: Pharmacogenomics Date: 2015-04-16 Impact factor: 2.533
Authors: Della Brown White; Vence L Bonham; Jean Jenkins; Nancy Stevens; Colleen M McBride Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-11 Impact factor: 4.254
Authors: Suzanne C O'Neill; George Luta; Beth N Peshkin; Anisha Abraham; Leslie R Walker; Kenneth P Tercyak Journal: J Pediatr Psychol Date: 2008-08-07
Authors: John K Chan; Thomas J Herzog; Lilian Hu; Bradley J Monk; Tuyen Kiet; Kevin Blansit; Daniel S Kapp; Xinhua Yu Journal: Oncologist Date: 2014-04-10
Authors: Louise Wideroff; Kathryn A Phillips; Gurvaneet Randhawa; Anita Ambs; Katrina Armstrong; Charles L Bennett; Martin L Brown; Molla S Donaldson; Michele Follen; Sue J Goldie; Robert A Hiatt; Muin J Khoury; Graham Lewis; Howard L McLeod; Margaret Piper; Isaac Powell; Deborah Schrag; Kevin A Schulman; Joan Scott Journal: Public Health Genomics Date: 2009-02-20 Impact factor: 2.000
Authors: Robert Cook-Deegan; Christopher DeRienzo; Julia Carbone; Subhashini Chandrasekharan; Christopher Heaney; Christopher Conover Journal: Genet Med Date: 2010-04 Impact factor: 8.822